Lipocine Inc (NAS:LPCN)

$ 5.06 0.2 (4.12%) Market Cap: 27.06 Mil Enterprise Value: 6.17 Mil PE Ratio: 0 PB Ratio: 1.41 GF Score: 41/100

Lipocine Inc at H.C. Wainwright Neuropsychiatry Virtual Conference Transcript
Jun 26, 2023
Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
Lipocine Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Lipocine Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Lipocine Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Lipocine Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 13, 2021
Lipocine Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 21, 2021
Lipocine Inc Summary Transcript
Jul 09, 2020

Lipocine Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 13, 2021 / 03:00PM GMT

Release Date Price: $22.44 (-2.22%)

Transcript

Matthew Kaplan

Ladenburg Thalmann & Co. Inc. - Analyst

I'd like to introduce our next presenting company, Lipocine. Presenting for the Company is Dr. Mahesh Patel, CEO. Mahesh, please walk us through the story. And hopefully we'll have some time for some Q&A afterwards. And thanks for joining us today and the floor is yours, Mahesh.

Mahesh Patel

Lipocine Inc. - Chairman, President & CEO

Thanks, Matt. It's my pleasure. Good day to everyone. I am Mahesh Patel; I am the President, CEO and Cofounder of Lipocine. I'm delighted to update you on our innovative and advancing pipeline, but let's get the forward-looking statement out of the way. I'll give you a few moments to -- all right, let's dive into our robust pipeline.

We are focused on developing innovative products for metabolic and endocrine disorders. We have one product that's standard. It would be approved. Two that are essentially Phase 3 really, and three in Phase 2 development. Our candidates are in three buckets -- testosterone replacement therapy, TLANDO. It is our convenient

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.